Literature DB >> 21189319

Differential microbicidal effects of human histone proteins H2A and H2B on Leishmania promastigotes and amastigotes.

Yingwei Wang1, Yang Chen, Lijun Xin, Stephen M Beverley, Eric D Carlsen, Vsevolod Popov, Kwang-Poo Chang, Ming Wang, Lynn Soong.   

Abstract

Recent studies have shown that histone proteins can act as antimicrobial peptides in host defense against extracellular bacteria, fungi, and Leishmania promastigotes. In this study, we used human recombinant histone proteins to further study their leishmaniacidal effects and the underlying mechanisms. We found that the histones H2A and H2B (but not H1(0)) could directly and efficiently kill promastigotes of Leishmania amazonensis, L. major, L. braziliensis, and L. mexicana in a treatment dose-dependent manner. Scanning electron microscopy revealed surface disruption of histone-treated promastigotes. More importantly, the preexposure of promastigotes to histone proteins markedly decreased the infectivity of promastigotes to murine macrophages (Mφs) in vitro. However, axenic and lesion-derived amastigotes of L. amazonensis and L. mexicana were relatively resistant to histone treatment, which correlated with the low levels of intracellular H2A in treated amastigotes. To understand the mechanisms underlying these differential responses, we investigated the role of promastigote surface molecules in histone-mediated killing. Compared with the corresponding controls, transgenic L. amazonensis promastigotes expressing lower levels of surface gp63 proteins were more susceptible to histone H2A, while L. major and L. mexicana promastigotes with targeted deletion of the lipophosphoglycan 2 (lpg2) gene (but not the lpg1 gene) were more resistant to histone H2A. We discuss the influence of promastigote major surface molecules in the leishmaniacidal effect of histone proteins. This study provides new information on host innate immunity to different developmental stages of Leishmania parasites.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21189319      PMCID: PMC3067510          DOI: 10.1128/IAI.00658-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  54 in total

1.  Translocation of histone proteins across lipid bilayers and Mycoplasma membranes.

Authors:  Joseph Rosenbluh; Elana Hariton-Gazal; Arie Dagan; Shlomo Rottem; Adolf Graessmann; Abraham Loyter
Journal:  J Mol Biol       Date:  2005-01-14       Impact factor: 5.469

2.  Type I IFN receptor regulates neutrophil functions and innate immunity to Leishmania parasites.

Authors:  Lijun Xin; Diego A Vargas-Inchaustegui; Sharon S Raimer; Brent C Kelly; Jiping Hu; Leiyi Zhu; Jiaren Sun; Lynn Soong
Journal:  J Immunol       Date:  2010-05-12       Impact factor: 5.422

3.  Stage-specific proteophosphoglycan from Leishmania mexicana amastigotes. Structural characterization of novel mono-, di-, and triphosphorylated phosphodiester-linked oligosaccharides.

Authors:  T Ilg; D Craik; G Currie; G Multhaup; A Bacic
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

Review 4.  Subversion mechanisms by which Leishmania parasites can escape the host immune response: a signaling point of view.

Authors:  Martin Olivier; David J Gregory; Geneviève Forget
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Genetic rescue of surface metalloproteinase (gp63)-deficiency in Leishmania amazonensis variants increases their infection of macrophages at the early phase.

Authors:  B McGwire; K P Chang
Journal:  Mol Biochem Parasitol       Date:  1994-08       Impact factor: 1.759

6.  The involvement of neutrophils in the resistance to Leishmania major infection in susceptible but not in resistant mice.

Authors:  Lin Chen; Zhi-Hui Zhang; Tadashi Watanabe; Takao Yamashita; Takatoshi Kobayakawa; Akira Kaneko; Hiromi Fujiwara; Fujiro Sendo
Journal:  Parasitol Int       Date:  2005-04-12       Impact factor: 2.230

7.  Temporins, small antimicrobial peptides with leishmanicidal activity.

Authors:  Maria Luisa Mangoni; José M Saugar; Maria Dellisanti; Donatella Barra; Maurizio Simmaco; Luis Rivas
Journal:  J Biol Chem       Date:  2004-10-28       Impact factor: 5.157

8.  Secreted proteophosphoglycan of Leishmania mexicana amastigotes activates complement by triggering the mannan binding lectin pathway.

Authors:  C Peters; M Kawakami; M Kaul; T Ilg; P Overath; T Aebischer
Journal:  Eur J Immunol       Date:  1997-10       Impact factor: 5.532

9.  The macrophage-attachment glycoprotein gp63 is the predominant C3-acceptor site on Leishmania mexicana promastigotes.

Authors:  D G Russell
Journal:  Eur J Biochem       Date:  1987-04-01

10.  Expression of lipophosphoglycan, high-molecular weight phosphoglycan and glycoprotein 63 in promastigotes and amastigotes of Leishmania mexicana.

Authors:  V Bahr; Y D Stierhof; T Ilg; M Demar; M Quinten; P Overath
Journal:  Mol Biochem Parasitol       Date:  1993-03       Impact factor: 1.759

View more
  34 in total

Review 1.  Extracellular histones in tissue injury and inflammation.

Authors:  Ramanjaneyulu Allam; Santhosh V R Kumar; Murthy N Darisipudi; Hans-Joachim Anders
Journal:  J Mol Med (Berl)       Date:  2014-04-06       Impact factor: 4.599

Review 2.  Histones as mediators of host defense, inflammation and thrombosis.

Authors:  Marloes Hoeksema; Martin van Eijk; Henk P Haagsman; Kevan L Hartshorn
Journal:  Future Microbiol       Date:  2016-03-04       Impact factor: 3.165

Review 3.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

Review 4.  Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis.

Authors:  Lynn Soong; Calvin A Henard; Peter C Melby
Journal:  Semin Immunopathol       Date:  2012-10-11       Impact factor: 9.623

5.  Intralesional uridine-5'-triphosphate (UTP) treatment induced resistance to Leishmania amazonensis infection by boosting Th1 immune responses and reactive oxygen species production.

Authors:  Camila Marques-da-Silva; Mariana M Chaves; Maria Luiza Thorstenberg; Vanessa R Figliuolo; Flávia S Vieira; Suzana P Chaves; José Roberto Meyer-Fernandes; Bartira Rossi-Bergmann; Luiz Eduardo Baggio Savio; Robson Coutinho-Silva
Journal:  Purinergic Signal       Date:  2018-04-21       Impact factor: 3.765

Review 6.  Permissive and protective roles for neutrophils in leishmaniasis.

Authors:  E D Carlsen; Y Liang; T R Shelite; D H Walker; P C Melby; L Soong
Journal:  Clin Exp Immunol       Date:  2015-08-28       Impact factor: 4.330

7.  Interactions between Neutrophils and Leishmania braziliensis Amastigotes Facilitate Cell Activation and Parasite Clearance.

Authors:  Eric D Carlsen; Zuliang Jie; Yuejin Liang; Calvin A Henard; Christie Hay; Jiaren Sun; Herbert de Matos Guedes; Lynn Soong
Journal:  J Innate Immun       Date:  2015-02-27       Impact factor: 7.349

8.  3'-nucleotidase/nuclease activity allows Leishmania parasites to escape killing by neutrophil extracellular traps.

Authors:  Anderson B Guimarães-Costa; Thiago S DeSouza-Vieira; Rafael Paletta-Silva; Anita Leocádio Freitas-Mesquita; José Roberto Meyer-Fernandes; Elvira M Saraiva
Journal:  Infect Immun       Date:  2014-02-10       Impact factor: 3.441

9.  Leishmania amazonensis amastigotes trigger neutrophil activation but resist neutrophil microbicidal mechanisms.

Authors:  Eric D Carlsen; Christie Hay; Calvin A Henard; Vsevolod Popov; Nisha Jain Garg; Lynn Soong
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

10.  Immunomodulatory Role of Clarithromycin in Acinetobacter baumannii Infection via Formation of Neutrophil Extracellular Traps.

Authors:  Theocharis Konstantinidis; Konstantinos Kambas; Alexandros Mitsios; Maria Panopoulou; Victoria Tsironidou; Erminia Dellaporta; Georgios Kouklakis; Athanasios Arampatzioglou; Iliana Angelidou; Ioannis Mitroulis; Panagiotis Skendros; Konstantinos Ritis
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.